Artisan Partners Limited Partnership Has $59.56 Million Stake in Repligen Co. (NASDAQ:RGEN)

Artisan Partners Limited Partnership reduced its stake in shares of Repligen Co. (NASDAQ:RGEN) by 5.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 413,747 shares of the biotechnology company’s stock after selling 23,544 shares during the quarter. Artisan Partners Limited Partnership owned 0.74% of Repligen worth $59,555,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Signaturefd LLC increased its position in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 124 shares in the last quarter. Resources Management Corp CT ADV acquired a new stake in shares of Repligen during the third quarter worth approximately $37,000. Quarry LP raised its stake in shares of Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 110 shares in the last quarter. Finally, Global Retirement Partners LLC grew its position in Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 129 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Stock Performance

Shares of Repligen stock opened at $137.12 on Friday. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $187.25. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a market capitalization of $7.70 billion, a price-to-earnings ratio of -268.86, a PEG ratio of 4.54 and a beta of 0.95. The firm has a fifty day moving average of $154.75 and a two-hundred day moving average of $148.22.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, equities research analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Insider Buying and Selling

In other news, Director Margaret Pax bought 250 shares of the business’s stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. JPMorgan Chase & Co. boosted their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. TD Cowen initiated coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Canaccord Genuity Group upped their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $180.00 price target on shares of Repligen in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Repligen presently has an average rating of “Hold” and a consensus target price of $178.64.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.